Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. At 406
2. At-406
3. At406 Cpd
4. Debio1143
5. N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
6. Sm 406
7. Sm-406
8. Sm406 Cpd
1. 1071992-99-8
2. At-406
3. Debio-1143
4. N65wc8pxdd
5. Sm-406
6. Unii-n65wc8pxdd
7. At406
8. (5s,8s,10ar)-n-benzhydryl-5-((s)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
9. At 406
10. Debio 1143
11. Sm 406
12. Xevinapant [inn]
13. Chembl2158051
14. Iap Inhibitor At-406
15. Debio-1143 (at-406)
16. At-406 (sm-406)
17. 1071992-99-8 (free Base)
18. At-406(at406)
19. D-1143
20. (5s,8s,10ar)-n-benzhydryl-5-[[(2s)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
21. Qcr-136
22. (5s,8s,10ar)-n-(diphenylmethyl)-5-[(n-methyl-l-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
23. At406 (sm-406)
24. Debio1143
25. Xevinapant [who-dd]
26. Gtpl7729
27. Schembl2724374
28. Dtxsid50648496
29. Ex-a104
30. Bcp04668
31. Bdbm50393505
32. Mfcd22124467
33. Nsc764757
34. S2754
35. Zinc43208643
36. Ccg-270056
37. Cs-0962
38. Nsc-764757
39. Ncgc00346675-01
40. Ncgc00346675-03
41. Ac-30282
42. As-56453
43. Hy-15454
44. D 1143
45. At406 (sm-406, Arry-334543)
46. J-501625
47. Q27074566
48. 1071992-99-8, 1071992-57-8 (hcl)
49. (5s,8s,10ar)-n-(diphenylmethyl)decahydro-5-(((2s)-2-(methylamino)-1-oxopropyl)amino)-3-(3-methyl-1-oxobutyl)-6-oxopyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
50. (5s,8s,10ar)-n-(diphenylmethyl)decahydro-5-[[(2s)-2-(methylamino)-1-oxopropyl]amino]-3-(3-methyl-1-oxobutyl)-6-oxopyrrolo[1,2-a][1,5 ]diazocine-8-carboxamide
51. Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, N-(diphenylmethyl)decahydro-5-(((2s)-2-(methylamino)-1-oxopropyl)amino)-3-(3-methyl-1-oxobutyl)-6-oxo-, (5s,8s,10ar)-
| Molecular Weight | 561.7 g/mol |
|---|---|
| Molecular Formula | C32H43N5O4 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 9 |
| Exact Mass | 561.33150487 g/mol |
| Monoisotopic Mass | 561.33150487 g/mol |
| Topological Polar Surface Area | 111 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 896 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Xevinapant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Xevinapant, including repackagers and relabelers. The FDA regulates Xevinapant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Xevinapant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Xevinapant supplier is an individual or a company that provides Xevinapant active pharmaceutical ingredient (API) or Xevinapant finished formulations upon request. The Xevinapant suppliers may include Xevinapant API manufacturers, exporters, distributors and traders.
Xevinapant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Xevinapant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Xevinapant GMP manufacturer or Xevinapant GMP API supplier for your needs.
A Xevinapant CoA (Certificate of Analysis) is a formal document that attests to Xevinapant's compliance with Xevinapant specifications and serves as a tool for batch-level quality control.
Xevinapant CoA mostly includes findings from lab analyses of a specific batch. For each Xevinapant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Xevinapant may be tested according to a variety of international standards, such as European Pharmacopoeia (Xevinapant EP), Xevinapant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Xevinapant USP).
LOOKING FOR A SUPPLIER?
